FOLFOX4 plus cetuximab for patients with previously untreated metastatic colorectal cancer according to tumor RAS and BRAF mutation status: Updated analysis of the CECOG/CORE 1.2.002 study

Clinical Colorectal Cancer

Volumn 14, Issue 2, 2015, Pages 91-98

  Kaczirek, Klaus ^a   Ciuleanu, Tudor E ^c   Vrbanec, Damir ^d   Marton, Erika ^b   Messinger, Diethelm ^e   Liegl Atzwanger, Bernadette ^f   Wrba, Fritz ^a   Knittelfelder, Regina ^g   Lindner, Elisabeth ^g   Zielinski, Christoph C ^a   Streubel, Berthold ^b   Brodowicz, Thomas ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^c THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^d KBC Zagreb   (Croatia)

^e Medical University of Graz ^*  (Germany)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

^g Central European Cooperative Oncology Group (CECOG)   (United States)

Author keywords

BRAF mutation; Cetuximab; FOLFOX4; Metastatic colorectal cancer; RAS mutation

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; CODON; GUANOSINE TRIPHOSPHATASE; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; ONCOPROTEIN; PLATINUM COMPLEX; RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CODON; CONTROLLED STUDY; EXON; FEMALE; GENE LOCUS; GENE MUTATION; GENETIC SCREENING; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; MUTATIONAL ANALYSIS; ONCOGENE; ONCOGENE BRAF; ONCOGENE K RAS; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PYROSEQUENCING; WILD TYPE; CANCER STAGING; CLINICAL TRIAL; COLORECTAL NEOPLASMS; FOLLOW UP; GENETICS; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SECONDARY; SURVIVAL RATE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CETUXIMAB; CODON; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; GTP PHOSPHOHYDROLASES; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84929517412     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2014.12.003     Document Type: Article

References (19)

1. J.Y. Douillard, S. Siena, and J. Cassidy Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study J Clin Oncol 28 2010 4697 4705
2. C. Bokemeyer, I. Bondarenko, and J.T. Hartmann Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study Ann Oncol 22 2011 1535 1546
3. E. Van Cutsem, C.H. Kohne, and I. Lang Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status J Clin Oncol 29 2011 2011 2019
4. J.Y. Douillard, K.S. Oliner, and S. Siena Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer N Engl J Med 369 2013 1023 1034
5. S. Tejpar, H. Lenz, and C. Köhne Effect of KRAS and NRAS mutations on treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated first-line with cetuximab plus FOLFOX4: new results from the OPUS study J Clin Oncol 2014 32 abstr LBA 444
6. T. Brodowicz, T.E. Ciuleanu, and D. Radosavljevic FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study Ann Oncol 24 2013 1769 1777
7. H. Ji, Z. Wang, and S.A. Perera Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models Cancer Res 67 2007 4933 4939
8. C. Bokemeyer, E. Van Cutsem, and P. Rougier Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials Eur J Cancer 48 2012 1466 1475
9. T.S. Maughan, R.A. Adams, and C.G. Smith Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial Lancet 377 2011 2103 2114
10. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
11. C. Bokemeyer, I. Bondarenko, and A. Makhson Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 2009 663 671
12. S. Stintzing, A. Jung, and L. Rossius Analysis of KRAS/NRAS and BRAF mutations in FIRE-3 Eur J Cancer 2013 49 abstr LBA 17
13. M. Karthaus, L. Schwartzberg, and F. Rivera Updated overall survival (OS) analysis of novel predictive KRAS/NRAS mutations beyond KRAS exon 2 in PEAK: a 1st-line phase 2 study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) in metastatic colorectal cancer (mCRC) Eur J Cancer 49 suppl 2 2013 abstr 2262
14. A.E. Karnoub, and R.A. Weinberg Ras oncogenes: split personalities Nat Rev Mol Cell Biol 9 2008 517 531
15. M. Janakiraman, E. Vakiani, and Z. Zeng Genomic and biological characterization of exon 4 KRAS mutations in human cancer Cancer Res 70 2010 5901 5911
16. Catalogue of somatic mutations in cancer. Available at: http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/. Accessed January 3, 2015.
17. A. Fernandez-Medarde, and E. Santos Ras in cancer and developmental diseases Genes Cancer 2 2011 344 358
18. M.T. Seymour, S.R. Brown, and G. Middleton Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial Lancet Oncol 14 2013 749 759
19. D.P. Modest, T. Brodowicz, and S. Stintzing Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials Oncology 83 2012 241 247